396 related articles for article (PubMed ID: 29560813)
1. Oligonucleotide therapeutics in neurodegenerative diseases.
Scoles DR; Pulst SM
RNA Biol; 2018; 15(6):707-714. PubMed ID: 29560813
[TBL] [Abstract][Full Text] [Related]
2. Antisense oligonucleotide therapy for spinocerebellar ataxia type 2.
Scoles DR; Meera P; Schneider MD; Paul S; Dansithong W; Figueroa KP; Hung G; Rigo F; Bennett CF; Otis TS; Pulst SM
Nature; 2017 Apr; 544(7650):362-366. PubMed ID: 28405024
[TBL] [Abstract][Full Text] [Related]
3. ALS-associated genes in SCA2 mouse spinal cord transcriptomes.
Scoles DR; Dansithong W; Pflieger LT; Paul S; Gandelman M; Figueroa KP; Rigo F; Bennett CF; Pulst SM
Hum Mol Genet; 2020 Jun; 29(10):1658-1672. PubMed ID: 32307524
[TBL] [Abstract][Full Text] [Related]
4. ATXN2-AS, a gene antisense to ATXN2, is associated with spinocerebellar ataxia type 2 and amyotrophic lateral sclerosis.
Li PP; Sun X; Xia G; Arbez N; Paul S; Zhu S; Peng HB; Ross CA; Koeppen AH; Margolis RL; Pulst SM; Ashizawa T; Rudnicki DD
Ann Neurol; 2016 Oct; 80(4):600-15. PubMed ID: 27531668
[TBL] [Abstract][Full Text] [Related]
5. [Antisense therapies for neurological diseases].
Pulst SM
Nervenarzt; 2019 Aug; 90(8):781-786. PubMed ID: 31165208
[TBL] [Abstract][Full Text] [Related]
6. Antisense Oligonucleotide Therapies for Neurodegenerative Diseases.
Bennett CF; Krainer AR; Cleveland DW
Annu Rev Neurosci; 2019 Jul; 42():385-406. PubMed ID: 31283897
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide CRISPR screen reveals v-ATPase as a drug target to lower levels of ALS protein ataxin-2.
Kim G; Nakayama L; Blum JA; Akiyama T; Boeynaems S; Chakraborty M; Couthouis J; Tassoni-Tsuchida E; Rodriguez CM; Bassik MC; Gitler AD
Cell Rep; 2022 Oct; 41(4):111508. PubMed ID: 36288714
[TBL] [Abstract][Full Text] [Related]
8. Electrophysiological Studies Support Utility of Positive Modulators of SK Channels for the Treatment of Spinocerebellar Ataxia Type 2.
Egorova PA; Bezprozvanny IB
Cerebellum; 2022 Oct; 21(5):742-749. PubMed ID: 34978024
[TBL] [Abstract][Full Text] [Related]
9. Staufen1 links RNA stress granules and autophagy in a model of neurodegeneration.
Paul S; Dansithong W; Figueroa KP; Scoles DR; Pulst SM
Nat Commun; 2018 Sep; 9(1):3648. PubMed ID: 30194296
[TBL] [Abstract][Full Text] [Related]
10. Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases.
Holm A; Hansen SN; Klitgaard H; Kauppinen S
RNA Biol; 2022; 19(1):594-608. PubMed ID: 35482908
[TBL] [Abstract][Full Text] [Related]
11. Generation of an Atxn2-CAG100 knock-in mouse reveals N-acetylaspartate production deficit due to early Nat8l dysregulation.
Sen NE; Canet-Pons J; Halbach MV; Arsovic A; Pilatus U; Chae WH; Kaya ZE; Seidel K; Rollmann E; Mittelbronn M; Meierhofer D; De Zeeuw CI; Bosman LWJ; Gispert S; Auburger G
Neurobiol Dis; 2019 Dec; 132():104559. PubMed ID: 31376479
[TBL] [Abstract][Full Text] [Related]
12. Antisense Oligonucleotides for the Study and Treatment of ALS.
Boros BD; Schoch KM; Kreple CJ; Miller TM
Neurotherapeutics; 2022 Jul; 19(4):1145-1158. PubMed ID: 35653060
[TBL] [Abstract][Full Text] [Related]
13. Antisense oligonucleotide-mediated ataxin-1 reduction prolongs survival in SCA1 mice and reveals disease-associated transcriptome profiles.
Friedrich J; Kordasiewicz HB; O'Callaghan B; Handler HP; Wagener C; Duvick L; Swayze EE; Rainwater O; Hofstra B; Benneyworth M; Nichols-Meade T; Yang P; Chen Z; Ortiz JP; Clark HB; Öz G; Larson S; Zoghbi HY; Henzler C; Orr HT
JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385727
[TBL] [Abstract][Full Text] [Related]
14. Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders.
Silva AC; Lobo DD; Martins IM; Lopes SM; Henriques C; Duarte SP; Dodart JC; Nobre RJ; Pereira de Almeida L
Brain; 2020 Feb; 143(2):407-429. PubMed ID: 31738395
[TBL] [Abstract][Full Text] [Related]
15. Antisense Drugs Make Sense for Neurological Diseases.
Bennett CF; Kordasiewicz HB; Cleveland DW
Annu Rev Pharmacol Toxicol; 2021 Jan; 61():831-852. PubMed ID: 33035446
[TBL] [Abstract][Full Text] [Related]
16. A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration.
Monine M; Norris D; Wang Y; Nestorov I
J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):639-654. PubMed ID: 33991294
[TBL] [Abstract][Full Text] [Related]
17. Degenerative ataxias, from genes to therapies: The 2015 Cotzias Lecture.
Pulst SM
Neurology; 2016 Jun; 86(24):2284-90. PubMed ID: 27298447
[TBL] [Abstract][Full Text] [Related]
18. Search for SCA2 blood RNA biomarkers highlights Ataxin-2 as strong modifier of the mitochondrial factor PINK1 levels.
Sen NE; Drost J; Gispert S; Torres-Odio S; Damrath E; Klinkenberg M; Hamzeiy H; Akdal G; Güllüoğlu H; Başak AN; Auburger G
Neurobiol Dis; 2016 Dec; 96():115-126. PubMed ID: 27597528
[TBL] [Abstract][Full Text] [Related]
19. A quantitative high-throughput screen identifies compounds that lower expression of the SCA2-and ALS-associated gene ATXN2.
Scoles DR; Gandelman M; Paul S; Dexheimer T; Dansithong W; Figueroa KP; Pflieger LT; Redlin S; Kales SC; Sun H; Maloney D; Damoiseaux R; Henderson MJ; Simeonov A; Jadhav A; Pulst SM
J Biol Chem; 2022 Aug; 298(8):102228. PubMed ID: 35787375
[TBL] [Abstract][Full Text] [Related]
20. Ataxin-2 gene: a powerful modulator of neurological disorders.
Laffita-Mesa JM; Paucar M; Svenningsson P
Curr Opin Neurol; 2021 Aug; 34(4):578-588. PubMed ID: 34010218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
